Iterum Therapeutics (ITRM) Competitors $0.76 +0.06 (+8.57%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$0.81 +0.05 (+6.58%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. IVVD, KALA, PYXS, EXOZ, ONCY, LFVN, SKYE, BMEA, CGEN, and HURAShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Invivyd (IVVD), KALA BIO (KALA), Pyxis Oncology (PYXS), eXoZymes (EXOZ), Oncolytics Biotech (ONCY), Lifevantage (LFVN), Skye Bioscience (SKYE), Biomea Fusion (BMEA), Compugen (CGEN), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors Invivyd KALA BIO Pyxis Oncology eXoZymes Oncolytics Biotech Lifevantage Skye Bioscience Biomea Fusion Compugen TuHURA Biosciences Invivyd (NASDAQ:IVVD) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Which has more volatility and risk, IVVD or ITRM? Invivyd has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Is IVVD or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -238.33%. Iterum Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-238.33% -177.89% -90.96% Iterum Therapeutics N/A N/A -65.01% Which has stronger earnings & valuation, IVVD or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$25.38M7.72-$169.93M-$0.92-1.77Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.89 Does the media prefer IVVD or ITRM? In the previous week, Invivyd had 14 more articles in the media than Iterum Therapeutics. MarketBeat recorded 14 mentions for Invivyd and 0 mentions for Iterum Therapeutics. Invivyd's average media sentiment score of 0.47 beat Iterum Therapeutics' score of 0.00 indicating that Invivyd is being referred to more favorably in the media. Company Overall Sentiment Invivyd Neutral Iterum Therapeutics Neutral Do institutionals & insiders have more ownership in IVVD or ITRM? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 25.4% of Invivyd shares are owned by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend IVVD or ITRM? Invivyd currently has a consensus price target of $5.14, suggesting a potential upside of 215.18%. Iterum Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 1,084.21%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Invivyd.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Iterum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryInvivyd and Iterum Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.02M$2.66B$6.11B$10.65BDividend YieldN/A56.92%5.70%4.74%P/E Ratio-0.8923.8685.6726.85Price / SalesN/A745.61623.73135.13Price / CashN/A169.9037.7861.77Price / Book-5.075.5913.246.70Net Income-$24.77M$32.78M$3.30B$276.44M7 Day Performance13.60%4.01%3.91%2.48%1 Month Performance15.10%10.63%8.37%8.79%1 Year Performance-20.66%-1.80%88.78%34.41% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics1.4885 of 5 stars$0.76+8.6%$9.00+1,084.2%-23.1%$33.02MN/A-0.8910Gap UpHigh Trading VolumeIVVDInvivyd3.5782 of 5 stars$1.12flat$3.18+184.2%+76.9%$134.56M$46.21M-1.22100Trending NewsAnalyst ForecastGap UpKALAKALA BIO4.1163 of 5 stars$2.05-89.2%$27.50+1,241.5%-69.3%$133.75M$3.89M-0.3030Short Interest ↑High Trading VolumePYXSPyxis Oncology1.8339 of 5 stars$2.20+2.8%$7.75+252.3%-25.0%$132.72M$2.82M-1.3760Gap UpEXOZeXoZymes0.9546 of 5 stars$14.50-6.3%N/AN/A$129.84M$70K0.0029Positive NewsONCYOncolytics Biotech1.5516 of 5 stars$1.41+9.3%$5.00+254.6%-3.6%$129.47MN/A-5.2230High Trading VolumeLFVNLifevantage4.2139 of 5 stars$9.76-4.2%$30.50+212.5%-20.8%$129.32M$228.53M13.19260News CoverageSKYESkye Bioscience2.6815 of 5 stars$3.88-5.6%$13.00+235.1%-56.8%$127.36MN/A-3.6611Trending NewsAnalyst DowngradeGap UpBMEABiomea Fusion3.4255 of 5 stars$2.06-1.9%$9.50+361.2%-82.3%$124.97MN/A-0.6850Trending NewsOptions VolumeGap DownCGENCompugen1.4693 of 5 stars$1.44+4.3%$4.00+177.8%-0.6%$123.15M$27.86M-6.5570Gap UpHURATuHURA Biosciences1.7753 of 5 stars$2.47+0.4%$12.67+412.8%N/A$123.11MN/A0.00N/A Related Companies and Tools Related Companies Invivyd Alternatives KALA BIO Alternatives Pyxis Oncology Alternatives eXoZymes Alternatives Oncolytics Biotech Alternatives Lifevantage Alternatives Skye Bioscience Alternatives Biomea Fusion Alternatives Compugen Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
